Baird analyst Joel Beatty lowered the firm’s price target on PTC Therapeutics (PTCT) to $66 from $70 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and where PKU PDUFA date is in July.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Revenue Performance and Promising Pipeline Present Compelling Buy Opportunity
- PTC Therapeutics price target lowered to $67 from $75 at JPMorgan
- PTC Therapeutics: Strong Financial Performance and Promising Product Launches Justify Buy Rating
- PTC Therapeutics upgraded to Neutral from Sell at Citi
- PTC Therapeutics Reports Strong Q1 2025 Results